Table 3. Safety Summary (all treated patients)

Variable	No. of Patients (%)			
	Cohort 1	Cohort 2	Cohort 3	All Patients
No. of patients	139	268	252	659
Total No. of patients with at least one AE	127 (91)	247 (92)	244 (97)	618 (94)
Adverse events				
Total No. of AEs	1,291	2,512	2,575	6,378
Grade 3 or 4	56 (40)	108 (40)	111 (44)	275 (42)
Grade 5	2 (1)	10 (4)	9 (4)	21 (3)
TRAEs				
All grades	81 (58)	173 (65)	175 (69)	429 (65)
Grade 3 or 4	13 (9)	35 (13)	33 (13)	81 (12)
Grade 5	0	0	1 (0.4)	1 (0.2)
SAEs	46 (33)	101 (38)	105 (42)	252 (38)
AEs leading to withdrawal from atezolizumab*	8 (6)	20 (8)	15 (6)	43 (7)
AEs leading to dose interruption	36 (26)	68 (25)	83 (33)	187 (28)
TRAEs leading to withdrawal from atezolizumab	5 (4)	4 (2)	6 (2)	15 (2)

NOTE. On the basis of a data cutoff of December 1, 2015.
Abbreviations: AE, adverse event; SAE, serious adverse event; TRAE, treatment-related adverse event.
*Causes of atezolizumab withdrawal (any grade; grade 3 to 4) occurring at an incidence ≥ 0.5% were pneumonitis (1%; 1%) and pneumonia (1%; 0%).

Table 3. Safety Summary (all treated patients)